TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04863638

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3-doses schedule 1 of COVID-19 Vaccine (Vero Cell), Inactivated
Description: the schedule of Day 0, 21, 42

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3-doses schedule 1 of COVID-19 Vaccine (Vero Cell), Inactivated
Description: the schedule of Day 0, 21, 42

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3-doses schedule 1 of COVID-19 Vaccine (Vero Cell), Inactivated
Description: the schedule of Day 0, 21, 42

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3-doses schedule 1 of COVID-19 Vaccine (Vero Cell), Inactivated
Description: the schedule of Day 0, 21, 42

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3-doses schedule 1 of COVID-19 Vaccine (Vero Cell), Inactivated
Description: the schedule of Day 0, 21, 42

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3-doses schedule 2 of COVID-19 Vaccine (Vero Cell), Inactivated
Description: the schedule of Day 0, 21, 111

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3-doses schedule 2 of COVID-19 Vaccine (Vero Cell), Inactivated
Description: the schedule of Day 0, 21, 111

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3-doses schedule 2 of COVID-19 Vaccine (Vero Cell), Inactivated
Description: the schedule of Day 0, 21, 111

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3-doses schedule 2 of COVID-19 Vaccine (Vero Cell), Inactivated
Description: the schedule of Day 0, 21, 111

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3-doses schedule 2 of COVID-19 Vaccine (Vero Cell), Inactivated
Description: the schedule of Day 0, 21, 111

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3-doses schedule 3 of COVID-19 Vaccine (Vero Cell), Inactivated
Description: the schedule of Day 0, 21, 171

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3-doses schedule 3 of COVID-19 Vaccine (Vero Cell), Inactivated
Description: the schedule of Day 0, 21, 171

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3-doses schedule 3 of COVID-19 Vaccine (Vero Cell), Inactivated
Description: the schedule of Day 0, 21, 171

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3-doses schedule 3 of COVID-19 Vaccine (Vero Cell), Inactivated
Description: the schedule of Day 0, 21, 171

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3-doses schedule 3 of COVID-19 Vaccine (Vero Cell), Inactivated
Description: the schedule of Day 0, 21, 171

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2 doses of vaccine
Description: the schedule of Day 0, 21

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2 doses of vaccine
Description: the schedule of Day 0, 21

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2 doses of vaccine
Description: the schedule of Day 0, 21
Study: NCT06045325

Intervention type: DIAGNOSTIC_TEST
Intervention: Orbscan II
Description: Diagnostic assessment to measure anterior chamber depth, white-to-white, and corneal thickness.

Intervention type: DIAGNOSTIC_TEST
Intervention: IOL Master 700
Description: Diagnostic assessment to measure anterior chamber depth, white-to-white, and corneal thickness.

Intervention type: DIAGNOSTIC_TEST
Intervention: IOL Master 500
Description: Diagnostic assessment to measure anterior chamber depth, white-to-white, and corneal thickness.

Intervention type: DIAGNOSTIC_TEST
Intervention: Atlas 9000
Description: Diagnostic assessment to measure white-to-white.

Intervention type: DIAGNOSTIC_TEST
Intervention: Lenstar 900
Description: Diagnostic assessment to measure anterior chamber depth, white-to-white, and corneal thickness.

Intervention type: DIAGNOSTIC_TEST
Intervention: Pentacam
Description: Diagnostic assessment to measure anterior chamber depth, white-to-white, and corneal thickness.

Intervention type: DIAGNOSTIC_TEST
Intervention: iTrace
Description: Diagnostic assessment to measure white-to-white and corneal thickness.

Intervention type: DIAGNOSTIC_TEST
Intervention: Argos
Description: Diagnostic assessment to measure anterior chamber depth, white-to-white, and corneal thickness.

Intervention type: DIAGNOSTIC_TEST
Intervention: Manual caliper measurement
Description: Manual diagnostic assessment to measure white-to-white.
Study: NCT05775328

Intervention type: OTHER
Intervention: Intense pulsed light
Description: Already described in the arm/group description
Study: NCT06406413

Intervention type: DIAGNOSTIC_TEST
Intervention: micro-movement; electroencephalogram; MRI
Description: micro-movement; electroencephalogram; MRI
Study: NCT05879562

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MoCA-Xpresso
Description: MoCA-Xpresso is a home-based, self-administered digital cognitive screening tool, based on a tablet device.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MoCA-Xpresso
Description: MoCA-Xpresso is a home-based, self-administered digital cognitive screening tool, based on a tablet device.
Study: NCT04970693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furmonertinib
Description: The different dose of furmonertinib will be given according to the generation of EGFR-TKI used as the first-line therapy. The doses and target volume of radiotherapy will be decided according to the oligoprogressive sites.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furmonertinib
Description: The different dose of furmonertinib will be given according to the generation of EGFR-TKI used as the first-line therapy. The doses and target volume of radiotherapy will be decided according to the oligoprogressive sites.
Study: NCT05103098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: misoprostol 400 mcg
Description: All patients will receive three doses of sublingual misoprostol every four hours The first dose of misoprostol 400 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of the second dose will be given upon sending home.~Two doses of misoprostol 400 mcg each (four tablets of 200 mcg per dose). Paracetamol, eight hourly, will be provided as an analgesic or antipyretic. A specimen bottle to collect the POC if passed out. Two pairs of disposable gloves. Pre-filled histopathological examination form to be sent to the laboratory together with the products of conception

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: misoprostol 800 mcg
Description: All patients will receive three doses of sublingual misoprostol every four hours The first dose of misoprostol 800 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of the second dose will be given upon sending home.~Two doses of misoprostol 800 mcg each (four tablets of 200 mcg per dose). Paracetamol, eight hourly, will be provided as an analgesic or antipyretic. A specimen bottle to collect the POC if passed out. Two pairs of disposable gloves. Pre-filled histopathological examination form to be sent to the laboratory together with the products of conception
Study: NCT05665322

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thermoablation with standard CT guidance
Description: Guidance with small volume breathing and high frequency. The contrast product will be venously injected in the elbow.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thermoablation with porto-scanner guidance with Angio-CT
Description: Real time guidance, small volume and high frequency respiration. Contrast medium will be directly injected into the superior mesenteric artery (SMA) after puncture of the femoral artery at the inguinal fold and catheterization of the SMA.
Study: NCT05377645

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cyriax mobilization + traditional physiotherapy
Description: TENS, US, exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cyriax mobilization + traditional physiotherapy
Description: TENS, US, exercise
Study: NCT05841056

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiodarone Hydrochloride 200 MG
Description: 200 mg daily for 4 weeks
Study: NCT04189510

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial Pancreas
Description: The Artificial Pancreas will delivery insulin in place of Multiple Daily Injections after a kidney transplant.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multiple Daily Injections
Description: Multiple Daily Injections as standard of care post kidney transplant.
Study: NCT05687318

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DeFrame
Description: DeFrame can analyze colonoscopy medical images generated by electronic digestive endoscopy equipment to automatically identify, label and screen capture polyps in the colon.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DeFrame
Description: DeFrame can analyze colonoscopy medical images generated by electronic digestive endoscopy equipment to automatically identify, label and screen capture polyps in the colon.
Study: NCT05226988

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: robot-assisted
Description: Participants received the 18-session robot-assisted intervention 3 sessions a week for 6 consecutive weeks. Each session consisted of 20-minute continuous passive motion, 20-minute active motion practice, and 30-minute task-oriented practice.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: robot-assisted
Description: Participants received the 18-session robot-assisted intervention 3 sessions a week for 6 consecutive weeks. Each session consisted of 20-minute continuous passive motion, 20-minute active motion practice, and 30-minute task-oriented practice.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: robot-assisted
Description: Participants received the 18-session robot-assisted intervention 3 sessions a week for 6 consecutive weeks. Each session consisted of 20-minute continuous passive motion, 20-minute active motion practice, and 30-minute task-oriented practice.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rehabilitation intervention
Description: Participants received the 18-session conventional rehabilitation intervention 3 sessions a week for 6 consecutive weeks. The intervention consisted of warm up including range of motion exercise, and strengthening exercise followed by task-oriented training for activities of daily living.
Study: NCT05643313

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ABLE Exoskeleton
Description: The ABLE Exoskeleton is a lower-limb overground robotic exoskeleton intended for SCI patients for rehabilitation in a clinical setting.
Study: NCT05127330

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LifePlans
Description: LifePlans is a video-based intervention, in which patients watch episodes starting during a psychiatric hospitalization and continuing through 1 month post-discharge. Other mental health treatment is unrestricted.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Individuals will receive unrestricted routine mental health care in the community as appropriate for their condition.
Study: NCT05051475

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic radiofrequency ablation
Description: Endoscopic ablation technique for Barrett's epithelium

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic hybrid argon plasma coagulation
Description: Endoscopic ablation technique for Barrett's epithelium
Study: NCT06230133

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBSR intervention
Description: In our study, it is the same to arm description.
Study: NCT05457322

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral intervention one
Description: Participants will view or listen to audiovisual material and engage in a daily 10-minute exercise. Following the practice period participants will continue to do the true 28-day intervention period in which they were randomized to.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral intervention two
Description: Participants will view or listen to audiovisual material and engage in a daily 10-minute exercise. Following the practice period participants will continue to do the true 28-day intervention period in which they were randomized to.
Study: NCT05012943

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARCT-154 Self-Amplifying RNA SARS-CoV-2 Vaccine
Description: ARCT-154 Self-Amplifying RNA SARS-CoV-2 Vaccine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (normal saline)
Description: Normal saline with the same volume as of ARCT-154

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Astra Zeneca COVID-19 vaccine
Description: Astra Zeneca COVID-19 vaccine (ChAdOx1 nCoV-19)
Study: NCT05257252

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Persons With Disability Friendly Nursing Education Program
Description: Persons With Disability Friendly Nursing Education Program developed based on the Story Theory, 2 weeks program
Study: NCT04953507

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thermal Radiofrequency
Description: Radiofrequency lesioning at level of T2, T3 using 80°c for 60-90 seconds

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Chemical Neurolysis
Description: injection of 2 to 3 ml of the chemical neurolytic agent (phenol in glycerin 6%)
Study: NCT01822951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cerebrolysin
Description: Intravenous medication is given in three treatment courses (TC). Each treatment course lasts for two weeks and consists of 10 infusions (5 infusions weekly). The first treatment course (TC 1) will be in Week 1 and 2, second treatment course (TC 2) will be repeated during Week 9 and 10 and third treatment course (TC 3) during Week 19 and 20.~Placebo for donepezil:1 tablet per day from TC 1 Day 1 on and 2 tablets per day from Visit 3 - Visit 5, p.o.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil
Description: 5-10 mg donepezil: 1x5 mg donepezil as 1 tablet per day from TC 1 Day 1 on and 2x5 mg donepezil as 2 tablets from Visit 3- Visit 5, p.o.~Intravenous medication is given in three treatment courses (TC). Each treatment course lasts for two weeks and consists of 10 infusions (5 infusions weekly). The first treatment course (TC 1) will be in Week 1 and 2, second treatment course (TC 2) will be repeated during Week 9 and 10 and third treatment course (TC 3) during Week 19 and 20.
Study: NCT05995457

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intramuscular injection of Haloperidol decanoate using the Z-track and Airlock techniques
Description: Intramuscular injection involves administering the drug treatment Haloperidol decanoate into muscle tissue using the Z-track and Airlock techniques

Intervention type: OTHER
Group type: OTHER
Intervention: Intramuscular injection of Haloperidol decanoate using standard techniques
Description: Intramuscular injection involves administering the drug Haloperidol decanoate into muscle tissue using the usual technique.
Study: NCT05223088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks for 3-6 weeks. Discontinuation will be considered due to toxicity, withdrawal of consent, or end of study. Every 3-week treatment period was considered to be a cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate
Description: Participants will receive apatinib, 250mg, qd，every 3 weeks for 2-5 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Participants will receive oxaliplatin, 130mg/m2, day 1 of every 3 weeks for 3-6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegafur
Description: Participants will receive Tegafur, day 1-14 of every 3 weeks for 3-6 weeks.
Study: NCT05792995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sindillimab
Description: Any treatment regimen that includes immunotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sindillimab
Description: Any treatment regimen that includes immunotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sindillimab
Description: Any treatment regimen that includes immunotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sindillimab
Description: Any treatment regimen that includes immunotherapy.
Study: NCT06083844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given by mouth
Study: NCT06308536

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bone powder + collagen membrane
Description: Fill the extraction socket with Bio-Oss® bone powder, and cover the extraction wound with Bio-Gide® collagen membrane.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone powder + collagen membrane + CGF membrane
Description: Fill the extraction socket with Bio-Oss® bone powder, and cover the extraction wound with Bio-Gide® collagen membrane plus CGF membrane(CGF gel is pressed into a film)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone powder mixed wih CGF gel + collagen membrane + CGF membrane
Description: Fill the extraction socket with Bio-Oss® bone powder mixed with CGF gel (CGF gel is cutted into granules ), and cover the extraction wound with Bio-Gide® collagen membrane plus CGF membrane(CGF gel is pressed into a film)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone powder + CGF membrane
Description: Fill the extraction socket with Bio-Oss® bone powder and cover the extraction wound with CGF membrane(CGF gel is pressed into a film)
Study: NCT04993599

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Social robot interaction
Description: The participants interact with the social robot which is controlled by the researcher behind the scene (wizard of oz. method).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Social robot interaction
Description: The participants interact with the social robot which is controlled by the researcher behind the scene (wizard of oz. method).
Study: NCT06233877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-GLIP plus Mitomycin C
Description: G-FLIP: Gemcitabine, Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin plus Mitomycin C
Study: NCT06302023

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA) 1000 mg
Description: Pregnant women will be ask to take a DHA 1000 mg per days at bedtime until delivery or 37 week of gestational age
Study: NCT06061055

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intubation with VentiBronc Anchor endobronchial double-lumen tube
Description: Patients in this group are intubated with triple-cuffed double-lumen endobronchial tube (VentiBronc Anchor).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional double-lumen intubation
Description: Patients in this group are intubated with conventional double-lumen endobronchial tube (Shiley).
Study: NCT05876871

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Pelvic Binder Radiography
Description: One series of radiographic exposures
Study: NCT06618053

Intervention type: OTHER
Intervention: cost-effectiveness and audiometry outcomes
Description: Evaluate cost-effectiveness of stapes surgery performed under local anesthesia as well as evaluate audiometry outcomes

Intervention type: OTHER
Intervention: cost-effectiveness and audiometry outcomes
Description: Evaluate cost-effectiveness of stapes surgery performed under local anesthesia as well as evaluate audiometry outcomes
Study: NCT06425666

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intervention group /arm 1 (Cataract surgery alone)
Description: Cataract surgery (arm 1) is performed using a small incision technique. The tunnel is used both for cataract surgery and for implantation of the DMEK graft (arm 2). The centres confirmed that the main incision will be localized between 11 and 12 o'clock and will have a width of 2.4 to 2.8 mm. A tunnel suture will only be placed if there is leakage from the incisions. If cataract surgery alone (arm 1) is performed, a thin dispersive viscoelastic is applied to the endothelium for protection before phacoemulsification. A hydrophobic acrylic monofocal IOL will be implanted into the bag. The centers confirmed that Barret Universal II formula is the standard IOL calculation formula for both groups and for all axial lengths.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Control group /arm 2: Corneal transplantation as Descemet Membrane Endothelial Keratoplasty (DMEK) in combination with cataract surgery (triple-DMEK)
Description: After cataract surgery DMEK is continued using the surgeon's standard technique for graft implantation and unfolding in triple-DMEK. In all cases the graft will be implanted using the same main incision as for IOL implantation. Once the DMEK graft is unrolled and attached to the posterior corneal stroma the complete anterior chamber will be filled with SF6 20%.
Study: NCT05161078

Intervention type: DEVICE
Intervention: CARPEDIEM
Description: CARPEDIEM treatment as per local standard of care
Study: NCT05228886

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SINCERE
Description: Each goal setting session will involve templated prompts in 211's ServicePoint to guide the creation of a patient-centered action plan specifying what, when, how much, and how often patients will engage in a behavior (e.g., I will work on filling out eligibility paperwork for 30 minutes on Wednesday evening). Again, following clear prompts, ISs negotiate the action plan with patients until patients can rate their level of confidence for achieving this behavior a 7 on a scale from 0 to 10.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Scheduled Follow-Up
Description: Adding to the standard Call + Resources protocol, those assigned to scheduled follow-up will receive a proactive call from 211 every 2 weeks for 3 months to explore additional service needs. These calls will be unstructured, guided by participant requests and 211 IS prompts.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: 211 ISs contact referred patients, provide referral services, and follow up in an ad-hoc manner.
Study: NCT04747990

Intervention type: PROCEDURE
Intervention: Early Definitive Treatment
Description: defined as treatment in accordance with the current guidelines (cholecystectomy or ERCP with endoscopic sphincterotomy during the same hospital admission or within 2 weeks of discharge)

Intervention type: PROCEDURE
Intervention: Early Definitive Treatment
Description: defined as treatment in accordance with the current guidelines (cholecystectomy or ERCP with endoscopic sphincterotomy during the same hospital admission or within 2 weeks of discharge)